|
Recombinant Respiratory Syncytial Virus (RSV) Firefly Luciferase Reporter Strain
Application
Modified recombinant syncytial virus (RSV) strain expressing a bioluminescent reporter protein for high throughput screening and vaccine development.
Key Benefits
Provides a new high throughput screening tool for RSV vaccine development and drug discovery.
Firefly luciferase based assays show better signal-to-noise than fluorescence-based...
Published: 4/23/2024
Contributor(s): Richard Plemper, Martin Moore
|
|
Assay for Non-Nucleoside Inhibitors of the Measles and Nipah Viruses
Application
A cell-based assay to screen for inhibitors of the measles virus (MV). Highly active compounds have been identified and analogs have been synthesized and evaluated.
Key Benefits
Potent (sub-nM range), non-peptidic, non-nucleosidic compounds.
Robust, cell-based, high-throughput screening assay.
Technical Summary
Vaccination serves...
Published: 4/23/2024
Contributor(s): Richard Plemper, James Snyder, Aiming Sun
|
|
Respiratory syncytial virus (RSV) Reporter Plasmid for High Throughput Drug Screening
Application
Bioluminescence reporter for high throughput respiratory syncytial virus (RSV) drug discovery.
Key Benefits
Simple luciferase readout marker indicates RSV replication activity.
Market Summary
RSV is a ubiquitous respiratory pathogen worldwide. It is the most common cause of severe lower respiratory tract disease among infants and young...
Published: 4/23/2024
Contributor(s): Martin Moore, Anne Hotard (Lopez-Ona), Richard Plemper
|
|
Respiratory Syncytial Virus (RSV) Luminescent Reporter Strain
Application
Modified respiratory syncytial virus (RSV) expressing a bioluminescent reporter protein for high throughput screening, vaccine development, and drug discovery. Plasmid encoding virus also available.
Key Benefits
Provides a new high throughput screening tool for RSV vaccine development and drug discovery.
Bioluminescent assays outperform...
Published: 4/23/2024
Contributor(s): Richard Plemper, Martin Moore
|
|
Small Molecule Non-Nucleoside Inhibitors of the Measles Viruses
Application
Small molecule measles virus RNA Dependent RNA Polymerase (RDRP) inhibitors.
Key Benefits
Potent (nM) non-nucleoside small molecule inhibitors of the measles virus RDRP protein.
No current drug therapy for measles.
Market Summary
The target market for this therapeutic agent is in the developing world where measles has been known...
Published: 4/23/2024
Contributor(s): Richard Plemper, James Snyder, Aiming Sun, John Maina Ndungu, Jeong-Joong Yoon
|
|
Small Molecule Inhibitors Show Promise with RNA Viruses
Application
Potent small molecule inhibitors of RNA viruses that cause many highly contagious and dangerous diseases such as canine distemper, RSV, influenza, and measles.
Key Benefits
Inhibits measles, canine distemper, human parainfluenza, and influenza A viruses.
May be used for the management of a disease and for rapid control of possible...
Published: 4/23/2024
Contributor(s): Richard Plemper, James Snyder, Aiming Sun, John Maina Ndungu, Jeong-Joong Yoon
|